117 related articles for article (PubMed ID: 15530779)
1. Targeting cell cycle and apoptosis for the treatment of human malignancies.
Senderowicz AM
Curr Opin Cell Biol; 2004 Dec; 16(6):670-8. PubMed ID: 15530779
[TBL] [Abstract][Full Text] [Related]
2. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Newton HB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531
[TBL] [Abstract][Full Text] [Related]
3. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.
Maddika S; Ande SR; Panigrahi S; Paranjothy T; Weglarczyk K; Zuse A; Eshraghi M; Manda KD; Wiechec E; Los M
Drug Resist Updat; 2007; 10(1-2):13-29. PubMed ID: 17303468
[TBL] [Abstract][Full Text] [Related]
4. Targeting the cell cycle: a new approach to cancer therapy.
Schwartz GK; Shah MA
J Clin Oncol; 2005 Dec; 23(36):9408-21. PubMed ID: 16361640
[TBL] [Abstract][Full Text] [Related]
5. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways.
Porter GW; Khuri FR; Fu H
Semin Cancer Biol; 2006 Jun; 16(3):193-202. PubMed ID: 16697216
[TBL] [Abstract][Full Text] [Related]
6. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of apoptosis pathways in cancer.
Ziegler DS; Kung AL
Curr Opin Oncol; 2008 Jan; 20(1):97-103. PubMed ID: 18043263
[TBL] [Abstract][Full Text] [Related]
8. Cyclins and related kinases in cancer cells.
Malumbres M
J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
[TBL] [Abstract][Full Text] [Related]
9. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145.
Yun JM; Kweon MH; Kwon H; Hwang JK; Mukhtar H
Carcinogenesis; 2006 Jul; 27(7):1454-64. PubMed ID: 16497706
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
[TBL] [Abstract][Full Text] [Related]
12. The role of cyclin-dependent kinases in apoptosis.
Borgne A; Golsteyn RM
Prog Cell Cycle Res; 2003; 5():453-9. PubMed ID: 14593740
[TBL] [Abstract][Full Text] [Related]
13. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
Simone M; Erba E; Damia G; Vikhanskaya F; Di Francesco AM; Riccardi R; Bailly C; Cuevas C; Fernandez Sousa-Faro JM; D'Incalci M
Eur J Cancer; 2005 Oct; 41(15):2366-77. PubMed ID: 16181779
[TBL] [Abstract][Full Text] [Related]
14. Magnolol elicits activation of the extracellular signal-regulated kinase pathway by inducing p27KIP1-mediated G2/M-phase cell cycle arrest in human urinary bladder cancer 5637 cells.
Lee SJ; Cho YH; Park K; Kim EJ; Jung KH; Park SS; Kim WJ; Moon SK
Biochem Pharmacol; 2008 Jun; 75(12):2289-300. PubMed ID: 18468578
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
[TBL] [Abstract][Full Text] [Related]
16. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
18. p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?
Levesque AA; Eastman A
Carcinogenesis; 2007 Jan; 28(1):13-20. PubMed ID: 17088261
[TBL] [Abstract][Full Text] [Related]
19. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic versus genotoxic potential of anti-tumor agents: a concept of duality in unity.
Bajic V; Milicevic Z; Potpervic-Spremo B; Nedeljkovic-Kurepa A
Med Hypotheses; 2003; 61(5-6):643-50. PubMed ID: 14592801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
